Alnylam Launches “Alnylam P5x25” Strategy For Planned Transition To A Top Five Biotech In Market Capitalization Over Next Five Years
Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.
* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the company’s announcement of complete financial results in ...
more
How did you like this article? Let us know so we can better customize your reading experience.
Comments
Leave a comment to automatically be entered into
our contest to win a free Echo Show.
